Lene Uhrbom
- Telephone:
- +46 18 471 50 63
- Mobile phone:
- +46 70 167 98 67
- E-mail:
- lene.uhrbom@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
More information is available to staff who log in.
Short presentation
Professor of Molecular brain tumor research
Keywords
- astrocyte
- brain
- cancer
- cell biology
- central nervous system
- glioblastoma
- glioma
- molecular biology
- neural stem cell
- neuro-oncology
- oligodendrocyte
- patient-derived models
Biography
2023, Professor of Molecular brain tumor research, Uppsala University
2015, Senior Lecturer of Molecular brain tumor research, Uppsala University
2005, Associate professor of Tumor biology, Uppsala University
2003, Assistant professor of Molecular genetic cancer research, Uppsala University
2001 - 2003, Postdoctoral researcher, Memorial Sloan-Kettering Cancer Center, New York
1999 - 2000, Postdoctoral researcher, Uppsala University
1999, PhD in Pathology, Uppsala University
Publications
Selection of publications
- Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival (2022)
- A molecularly distinct subset of glioblastoma requires serum-containing media to establish sustainable bona fide glioblastoma stem cell cultures (2020)
- LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients (2019)
- Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin (2017)
- Mouse models of pediatric supratentorial high-grade glioma reveal how cell-of-origin influences tumor development and phenotype (2017)
- The Human Glioblastoma Cell Culture Resource (2015)
- Oncogenic Signaling Is Dominant to Cell of Origin and Dictates Astrocytic or Oligodendroglial Tumor Development from Oligodendrocyte Precursor Cells (2014)
- Oligodendroglioma models (2013)
- On the origin of glioma (2012)
- RAD51 can inhibit PDGFB-induced gliomagenesis and genomic instability (2011)
- Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma (2009)
- Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence (2009)
- Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma (2007)
- Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. (2005)
- Somatic cell gene transfer (2004)
- Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. (2004)
- Dissecting gliomagemesis using glial-specifictransgenic mouse models (2003)
- Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. (2003)
- Ink4a-Arf loss cooperates with KRas activation in astrocytes and neuralprogenitors to generate glioblastomas of various morphologies depending onactivated Akt. (2002)
- Glial tumors of the CNS (2001)
- Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors. (2001)
- Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells (2000)
- Induction of brain tumors in mice using a recombinant PDGF B retrovirus (1998)
- Induction of senescence in human malignant glioma cells by p16INK4A (1997)
Recent publications
- Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures (2023)
- Live Detection of Neural Progenitors and Glioblastoma Cells by an Oligothiophene Derivative (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas (2023)
- Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma (2023)
All publications
Articles
- Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures (2023)
- Live Detection of Neural Progenitors and Glioblastoma Cells by an Oligothiophene Derivative (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas (2023)
- Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma (2023)
- Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival (2022)
- Key molecular alterations in endothelial cells in human glioblastoma uncovered through single-cell RNA sequencing (2021)
- FACT-seq (2021)
- A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma (2020)
- A molecularly distinct subset of glioblastoma requires serum-containing media to establish sustainable bona fide glioblastoma stem cell cultures (2020)
- BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells (2019)
- Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors (2019)
- LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients (2019)
- Snail regulates BMP and TGF beta pathways to control the differentiation status of glioma-initiating cells (2018)
- Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity (2018)
- Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin (2017)
- Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses (2017)
- Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential (2017)
- Mouse models of pediatric supratentorial high-grade glioma reveal how cell-of-origin influences tumor development and phenotype (2017)
- Case-specific potentiation of glioblastoma drugs by pterostilbene (2016)
- Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition (2016)
- ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells (2016)
- Pleiotrophin enhances PDGFB-induced gliomagenesis through increased proliferation of neural progenitor cells (2016)
- Etomidate, propofol and diazepam potentiate GABA-evoked GABAA currents in a cell line derived from Human glioblastoma (2015)
- Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells (2015)
- The Human Glioblastoma Cell Culture Resource (2015)
- GABA-A receptor currents in a cell line (U3047MG) derived from a human glioblastoma tumor are enhanced by etomidate, propofol and diazepam (2014)
- Oncogenic Signaling Is Dominant to Cell of Origin and Dictates Astrocytic or Oligodendroglial Tumor Development from Oligodendrocyte Precursor Cells (2014)
- Selective Calcium Sensitivity in Immature Glioma Cancer Stem Cells (2014)
- Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions (2013)
- Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures (2013)
- On the origin of glioma (2012)
- miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma (2012)
- Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells (2011)
- PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation (2011)
- Mast Cell Accumulation in Glioblastoma with a Potential Role for Stem Cell Factor and Chemokine CXCL12 (2011)
- CGGBP1 regulates cell cycle in cancer cells (2011)
- RAD51 can inhibit PDGFB-induced gliomagenesis and genomic instability (2011)
- Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma (2009)
- Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma (2009)
- IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas (2009)
- Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence (2009)
- Sox10 Has a Broad Expression Pattern in Gliomas and Enhances Platelet-Derived Growth Factor-B–Induced Gliomagenesis (2007)
- Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma (2007)
- Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. (2005)
- Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging (2004)
- Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. (2004)
- Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. (2003)
- p190RhoGAP can act to inhibit PDGF-induced gliomas in mice (2003)
- Ink4a-Arf loss cooperates with KRas activation in astrocytes and neuralprogenitors to generate glioblastomas of various morphologies depending onactivated Akt. (2002)
- Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors. (2001)
- Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells (2000)
- Induction of brain tumors in mice using a recombinant PDGF B retrovirus (1998)
- Induction of senescence in human malignant glioma cells by p16INK4A (1997)
- Targeting SOX2 in glioblastoma cells reveals heterogeneity in SOX2 dependency
- Paired glioblastoma cell cultures of the fluorescent bulk tumor and non-fluorescent tumor margin display differential phenotypes and cell states across patients
Chapters
